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Summary
Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis 
than urothelial carcinoma of the urinary bladder. No international consensus exists on the benefit of adjuvant 
chemotherapy for patients with UTUCs after nephroureterectomy with curative intent. The POUT trial aimed to 
assess the efficacy of systemic platinum-based chemotherapy in patients with UTUCs. [A: can you define POUT?]
Methods We did a phase 3, open-label, randomised controlled trial (the POUT trial) at 71 hospitals in the UK. We 
recruited patients with UTUC after nephroureterectomy staged as either pT2–T4 pN0–N3 M0 or pTany N1–3 M0. We 
randomly allocated participants centrally (1:1) to either surveillance or four 21-day cycles of chemotherapy, using a 
minimisation algorithm with a random element. Chemotherapy was either cisplatin (70 mg/m²) or carboplatin 
(AUC4·5/AUC5, for reduced GFR [<50 mL/min] only) administered intravenously on day 1 and gemcitabine 
(1000 mg/m²) administered intravenously on days 1 and 8; chemotherapy was initiated within 90 days of surgery. 
Follow-up included standard cystoscopic, radiological, and clinical assessments. The primary endpoint was disease-
free survival analysed by intention to treat with a Peto-Haybittle stopping rule for (in)efficacy. The trial is registered 
with ClinicalTrials.gov, NCT01993979. A preplanned interim analysis met the efficacy criterion for early closure after 
recruitment of 261 participants.
Findings Between June 19, 2012, and Nov 8, 2017, we enrolled 262 participants from 56 of 71 open study sites. [A: note 
that in the appendix there are 57 centres listed] 132 patients were assigned chemotherapy and 129 surveillance. 
One participant allocated chemotherapy withdrew consent for data use after randomisation and was excluded from 
analyses. Adjuvant chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; 
p=0·00017) at a median follow-up of 30·3 months (IQR 18·0–47·5). 3-year event-free estimates were 71% (95% CI 
61–78) and 46% (36–56) for chemotherapy and surveillance, respectively. 55 (44%) of 126 participants who started 
chemotherapy and five (4%) of 129 patients managed by surveillance had acute grade 3 or worse treatment-emergent 
adverse events, which accorded with frequently reported events for the chemotherapy regimen. No treatment-related 
deaths were reported.
Interpretation Gemcitabine-platinum combination chemotherapy initiated within 90 days after nephroureterectomy 
significantly improved disease-free survival in patients with locally advanced UTUC. Adjuvant platinum-based 
chemotherapy should be considered a new standard of care after nephroureterectomy for this patient population.
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Introduction
[A: We have edited your paper to avoid repetition, enhance 
readability, reduce length, and achieve consistency with 
Lancet style.]
Upper tract urothelial carcinoma (UTUC; transitional 
cell carcinoma of the ureter or renal pelvis) is rare, 
occurring in around two people per 100 000 population 
in high-income countries. Scant symptoms and delayed 
diagnosis mean that tumours are usually muscle-invasive 
or locally advanced at presentation (56%), resulting in 
poorer survival figures than for urothelial carcinoma of the 
urinary bladder. More than 50% of patients diagnosed with 
UTUC die as a result of their disease, despite systemic 
platinum-based chemotherapy after local or metastatic 
recurrence.1 Improved management of early-stage disease, 
therefore, has the potential to save lives. At the inception 
of this study, systemic treatment had no proven role for 
locally advanced UTUC. Nephroureterectomy followed 
by surveillance has remained the routine treatment for 
localised UTUC.1
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UTUC shares several clinicopathological features with 
muscle-invasive urothelial (transitional cell) carcinoma 
of the bladder. Robust survival improvements are seen 
with platinum-based chemotherapy in patients with 
urothelial bladder cancer, in both the neoadjuvant and 
metastatic settings.2–4 Similar benefits of platinum-based 
palliative chemotherapy have been seen for UTUC and 
urothelial bladder cancer at advanced stages.5 Thus, a 
clear rationale exists for investigating perioperative, 
platinum-based chemotherapy in patients with UTUC.
Because of the strength of evidence showing survival 
gain, neoadjuvant chemotherapy is the accepted standard 
of care for muscle-invasive bladder cancer. Although a 
neoadjuvant approach is attractive for patients with 
UTUC, particularly when the loss of renal function asso-
ciated with nephrectomy is considered, the unreliability of 
preoperative UTUC staging and histopathology would 
probably result in over-treatment for some patients and 
under-treatment for others.6 Previous studies of adjuvant 
chemotherapy in UTUC are largely retrospective, with 
low statistical power and conflicting conclusions,7–9 pro-
viding insufficient evidence to recommend perioperative 
chemotherapy. Thus, for many patients with muscle-
invasive UTUC, surgery alone is considered the standard 
approach.
Patient-reported outcome data for this rare population 
are also absent, with most available published work at 
the outset of this trial focusing on short-term outcomes 
after nephroureterectomy and no data obtained within 
the context of randomised controlled trials. We aimed to 
prospectively assess in a randomised controlled trial 
(the POUT trial) the effect of adjuvant platinum-based 
chemotherapy on disease-free survival, overall survival, 
safety, and quality of life after radical nephroureterectomy 
in patients with locally advanced UTUC.
Methods
Study design
POUT is a phase 3, parallel group, open-label, randomised 
controlled trial at 71 National Health Service (NHS) 
hospitals in the UK. An intervention was included to 
understand and then support recruitment to the trial.10 
Eligible patients were aged at least 16 years, had received 
en-bloc radical nephroureterectomy for UTUC (including 
resection of all radiologically or macroscopically abnormal 
nodes), were postoperatively staged with either muscle-
invasive (pT2–pT4, Nany) or lymph node-positive (pTany, 
N1–3) metastasis-free (M0) disease with predominantly 
transitional cell carcinoma histology, and were fit to receive 
adjuvant chemotherapy within 90 days after surgery.
Formal extended lymph-node dissection was not 
mandated. Participants with lymph-node involvement 
identified on preoperative imaging or during surgery 
had all grossly abnormal nodes resected. Postoperative 
imaging was mandated for these patients before 
randomisation; those with residual lymphadenopathy as 
ascertained by the local investigator were excluded. Par-
ticipants had satisfactory haematological and biochemical 
blood profiles and a glomerular filtration rate (GFR) of 
30 mL/min or higher.
Research in context
Evidence before this study
Before this study, little previous research had been done 
assessing the efficacy of systemic chemotherapy for locally 
advanced upper tract urothelial carcinoma (UTUC), partly 
because of the rarity of the disease. Undersized or retrospective 
studies had not shown a convincing survival benefit for 
chemotherapy. International guidelines, [A: which ones?] 
therefore, recommended nephroureterectomy followed by 
surveillance as the standard of care. [A: did you do a literature 
search before your study? Please say which databases you 
searched, keywords used, and give the dates between which 
you searched. Please also say if you restricted your search by 
language or type of publication] Most urothelial carcinomas 
(in both UTUC and bladder cancer) originate in the transitional 
epithelium (transitional cell carcinoma). It is logical, therefore, 
to consider data from trials of systemic bladder cancer 
treatment for signals to indicate whether chemotherapy could 
be efficacious in UTUC. Studies of perioperative chemotherapy 
for primary urothelial carcinoma of the bladder suggested 
localised urothelial carcinoma was chemosensitive, with 
(on meta-analysis) cisplatin-based neoadjuvant chemotherapy 
showing an absolute improvement of 5% in overall survival at 
5 years (hazard ratio 0.86, 95% CI 0.77–0.95; p=0·003). 
Therefore, a comparable trial in UTUC was justified, particularly 
in view of the inferior stage-for-stage outcomes in UTUC when 
compared with bladder urothelial carcinoma. Challenges of 
obtaining definitive histology and accurate staging for UTUC 
before nephroureterectomy risk either undertreatment or 
overtreatment with neoadjuvant therapy. The POUT trial was, 
therefore, designed as a phase 3 randomised trial of adjuvant 
platinum-based chemotherapy, intended to provide, for the 
first time, robust evidence regarding its efficacy in UTUC.
Added value of this study
To the best of our knowledge, our study is the largest 
randomised controlled clinical trial done exclusively in patients 
with UTUC worldwide.
Implications of all the available evidence
We have shown that giving adjuvant platinum-based 
chemotherapy within 90 days after nephroureterectomy 
reduces subsequent rates of disease recurrence. Our data, 
therefore, suggest that adjuvant platinum-based chemotherapy 
should be recommended as a new standard of care after 
nephroureterectomy for all patients with locally advanced UTUC 
in whom there are no definitive contraindications to 
chemotherapy.
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Participants were recruited by their clinical care teams 
and provided written informed consent before enrolment. 
Regulatory approvals were obtained before trial activation 
from the Medicines and Healthcare products Regulatory 
Agency (MHRA) and the North West–Greater Manchester 
South research ethics committee (11/NW/0782). The 
POUT trial was undertaken according to the principles of 
Good Clinical Practice. The Clinical Trials and Statistics 
Unit at The Institute of Cancer Research (ICR-CTSU) 
coordinated the trial, did central statistical data moni-
toring, and undertook all analyses. The trial management 
group was overseen by independent data monitoring 
and trial steering committees. The full study protocol is 
available XX. [A: Is the protocol available via a URL we 
can link in the margin? This is usually a better solution 
for readers and to keep the supplementary material 
short. If not, please add it to the end of your current 
appendix PDF].
Randomisation and masking
Treatment allocation was done centrally by ICR-CTSU 
using a minimisation algorithm incorporating a random 
element. Balancing factors were planned platinum agent 
(cisplatin vs carboplatin), preoperative radiologically or 
pathologically assessed nodal involvement (N0 vs N1 
vs N2 vs N3), status of microscopic surgical margins 
(positive vs negative), and treating centre. Participants 
were randomly allocated (1:1) to either surveillance or 
chemotherapy. Treatment allocation was not masked.
Procedures
Participants allocated chemotherapy received four 21-day 
cycles of platinum-based combination chemotherapy, to 
begin within 14 days after randomisation. Gemcitabine 
(1000 mg/m²) was given on days 1 and 8 of each cycle. 
Either cisplatin (70 mg/m²) or carboplatin (AUC 4·5 or 
AUC5, according to local practice, prespecified for each 
treatment centre) was given on day 1. Impaired renal 
function (GFR ≥30 mL/min and <50 mL/min) was the 
only permitted reason to give carboplatin rather than 
cisplatin. Protocol-specified recommendations were for 
chemotherapy to begin within 90 days of nephro-
ureterectomy, for gemcitabine to be given as a 30-min 
intravenous infusion in 500 mL normal saline, cisplatin 
as a 4-h intravenous infusion in 1 L saline, and carboplatin 
as a 1-h intravenous infusion. Use of generic agents was 
allowed; no recommended manufacturer was specified. 
Hydration and infusion rates were in accordance with 
local practice. The protocol-recommended calculation of 
GFR was by the Cockcroft and Gault method; however, 
use of the Wright formula or estimation by radioiso-
tope clearance were also permitted. Participating sites 
prespecified their intended assessment method before 
activation and were requested to use the same GFR 
assessment method for a participant throughout the 
study. Patients otherwise unsuitable to receive cisplatin 
were not permitted to join the trial to minimise the 
potential confounding effects of frailty and comorbidity. 
All participants receiving chemotherapy had haema-
tology and serum biochemistry assessments and their 
GFR was estimated and body surface area calculated 
before every cycle of chemotherapy.
Adverse events during every chemotherapy cycle were 
assessed [A: by whom?] using National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0. Participants allocated surveillance 
underwent adverse event assessment every 3 weeks after 
randomisation to mirror the assessment schedule of 
participants allocated chemotherapy. Protocol-specified 
dose modifications were permitted for toxic effects of 
CTCAE grade 3 or worse. Patients intended to receive 
cisplatin were to switch to carboplatin if the estimated 
GFR fell to 30–49 mL/min. If the GFR fell from 
70 mL/min or higher to 50–69 mL/min then the cisplatin 
dose was allowed to be split across 2 consecutive days.
Participants in both study groups were followed up at 3, 
6, 9, and 12 months, then every 6 months to 36 months 
from randomisation, regardless of whether chemotherapy 
was complete, and annually thereafter. Assessment of 
disease recurrence included either plain film radiography 
or cross-sectional imaging (CT) of the thorax plus CT of 
the abdomen and pelvis at 3, 6, 9 (thorax only), 12, 18, 24, 30 
(thorax only), and 36 months then annually to 60 months. 
Cystoscopy was done every 6 months to 24 months, 
then annually to 60 months to detect recurrence in the 
lower urinary tract. Follow-up assessments were done in 
accordance with standard practice in the UK at time. 
Assessment of adverse events was done at every follow-
up visit to 24 months. Participants in both study groups 
who had disease recurrence were permitted to receive 
any appropriate further treatment as clinically indicated, 
including platinum-gemcitabine chemotherapy.
Participants in an optional patient-reported quality-of-life 
substudy were asked to complete on paper the European 
Organisation for Research and Treatment of Cancer 
(EORTC) quality-of-life of cancer patients questionnaire 
(QLQ-C30) and the EuroQol five dimensions five levels 
questionnaire (EQ-5D-5L) at baseline and before cycle 
three (week 7) and at 3 months, then at 6, 12, and 24 months 
post randomisation.
Outcomes
The primary endpoint was disease-free survival according 
to local assessment and was defined as time from 
randomisation to either first recurrence in the tumour 
bed, first metastasis, or death from any cause. Recurrence 
and metastasis could be established either radiologically 
or pathologically. Patients were censored at the date of 
diagnosis of a second primary cancer (including muscle-
invasive bladder cancer and contralateral UTUC). New 
non-muscle-invasive bladder cancer was not regarded 
as an event or a reason to censor, although such events 
were recorded for future analysis. Secondary end-
points included metastasis-free survival, overall survival, 
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treatment compliance, acute toxicity, late toxicity, and 
patient-reported quality of life.
Statistical analysis
The trial was designed to detect a hazard ratio (HR) of 
0·65 in favour of chemotherapy, equivalent to a 15% 
absolute improvement in 3-year disease-free survival 
(from 40% to 55%, which was chosen to correspond with 
the magnitude of benefit noted for chemotherapy in 
muscle-invasive bladder cancer), with a two-sided signifi-
cance of 5% and 80% power. On this basis, target 
recruitment was 345 participants (172 events), including 
a 2% inflation for loss to follow-up.
Time-to-event endpoints were analysed according to 
the intention-to-treat principle using the log-rank test 
and are presented using Kaplan-Meier plots. Estimates 
of treatment effect (with 95% CIs) were made using 
unadjusted and adjusted Cox regression models, with 
an HR less than 1 favouring chemotherapy. Adjusted 
models included planned chemotherapy type, nodal 
status and microscopic margin status (balancing factors) 
and pathological stage. A prespecified subgroup ana-
lysis was done of adjustment factors. The proportional 
hazards assumption of the Cox model held when tested 
with Schoenfeld residuals. Two-sided p values less than 
0·05 were judged significant.
The incidence of acute treatment-emergent adverse 
events, defined for both study groups as an increase in 
grade of any adverse event from baseline up to the 
3-month timepoint, was compared by treatment received 
using the Wilcoxon rank-sum test (worst grade) and the 
χ² test (proportion grade 3 or worse). Adverse events 
reported by more than 10% of participants in either 
group, or with significant differences between study 
groups using the Wilcoxon rank-sum test with a 1% 
significance level (to make some adjustment for multiple 
testing), were judged meaningful. Toxicity and treatment 
compliance data are reported by treatment received 
at cycle one. Treatment compliance was assessed in 
the safety population, which included all participants 
allocated surveillance and all allocated chemotherapy 
who had at least one dose of gemcitabine, cisplatin, 
or carboplatin. [A: OK to add text?] When comparing 
the frequency of each adverse event type, we excluded 
participants who were not assessed for that adverse event 
type in the first 3 months of treatment (or equivalent 
timepoints for those allocated surveillance).
The global health score of the EORTC QLQ-C30 
reported up to 12 months was summarised according to 
randomised allocation on an intention-to-treat basis. 
Data were analysed in accordance with the QLQ-C30 
Figure 1: Trial profile
*XX. [A: please indicate what * refers to. Are the dotted arrows to indicate 
crossovers? What do the numbers represent (they are correct for crossovers 
up to cycle 2 and then don’t tally)?]
131 in ITT population
126 received chemotherapy
35 disease-free survival events
24 deaths
(ITT population)
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)
76 planned to receive 
gemcitabine-cisplatin
50 planned to receive 
gemcitabine-carboplatin
71 cycle 1 
gemcitabine-cisplatin
69 (97%) without dose 
reduction
55 cycle 1 
gemcitabine-carboplatin
54 (98%) without dose 
reduction
57 cycle 2 
gemcitabine-cisplatin
50 (88%) without dose 
reduction
57 cycle 2 
gemcitabine-carboplatin
38 (67%) without dose 
reduction
48 cycle 3 
gemcitabine-cisplatin
42 (88%) without dose 
reduction
58 cycle 3 
gemcitabine-carboplatin
50 (86%) without dose 
reduction
42 cycle 4 
gemcitabine-cisplatin
37 (88%) without dose 
reduction
53 cycle 4 
gemcitabine-carboplatin
44 (83%) without dose 
reduction
133 underwent surveillance
261 participants enrolled and  randomly assigned
60 disease-free survival events
38 deaths
(ITT population)
129 in ITT population 
132 allocated adjuvant 
chemotherapy
129 allocated surveillance 
2 switched to chemotherapy 
after recruitment closure  
1 ineligible (concurrent 
muscle-invasive bladder 
cancer)
7 did not receive allocated 
treatment
5 patient’s decision
2 clinical decision
1 excluded (withdrew 
consent after 
randomisation)
16
6*
3*
1*
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scoring manual. Change from baseline was compared 
between randomised groups using the ANCOVA model, 
adjusting for baseline score. Allowance for multiple 
testing was made by assessing scores at 3 months and 
12 months only, with p values less than 0·01 judged 
significant; as a result, 99% CIs were used.
Accumulating safety and efficacy data were reviewed in 
confidence annually throughout the trial by an inde-
pendent data monitoring committee. A Peto-Haybittle 
stopping rule (p<0·001) addressed both efficacy and 
inefficacy in disease-free survival.
Analyses are based on a snapshot of data taken on 
Nov 7, 2018, and include data from all follow-up visits up 
to and including May 31, 2018. This snapshot supersedes 
that used for the interim analysis, which led to the 
decision to close the trial early so that complete treatment 
and 3-month toxicity data could be reported. Analyses 
were done using Stata version 15.1.
This study is registered with controlled-trials.com 
(ISRCTN98387754), ClinicalTrials.gov (NCT01993979), 
and Cancer Research UK (CRUK/11/027).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between June 19, 2012, and Nov 8, 2017, 261 participants 
were recruited from 56 of 71 open sites (appendix pp 2–4), 
[A: please note that the appendix lists 57 sites] of whom 
132 patients were allocated chemotherapy and 129 were 
allocated surveillance. 260 participants were included 
in the intention-to-treat population; one participant with-
drew consent for data use after randomisation and is not 
included in any analyses (figure 1). Recruitment closed 
early on the recommendation of the independent data 
monitoring committee, having met the early stopping 
criterion for efficacy. At the point of trial closure, the 
independent data monitoring committee recommended 
that all participants who were still within the 90-day 
window from nephroureterectomy should be offered 
chemotherapy. Two participants allocated surveillance 
and still within this timeframe crossed over to receive 
chemotherapy but were included in the surveillance group 
for the intention-to-treat analysis (figure 1).
The median age of participants was 68.5 years 
(IQR 62·0–74·1; table). 245 (94%) of 260 participants 
were staged pT2–T3; of these, 223 (91%) were also 
staged N0 (appendix p 5). 166 (64%) participants had 
GFR of 50 mL/min or higher. [A: meaning the remaining 
94 patients had impaired renal function (according to 
your definition in the Methods), and 49 were planned to 
have carboplatin (in table), according to the protocol? 
Can you explain any differences in the number receiving 
Surveillance (n=129) Chemotherapy (n=131) Total (n=260)
Sex
Male 83 (64%) 93 (71%) 176 (68%)
Female 46 (36%) 38 (29%) 84 (32%)
Age group (years)
<50 5 (4%) 5 (4%) 10 (4%)
50–59 24 (19%) 19 (15%) 43 (17%)
60–69 52 (40%) 50 (38%) 102 (39%)
70–79 40 (31%) 51 (39%) 91 (35%)
≥80 8 (6%) 6 (5%) 14 (5%)
Median (IQR) 66·5 (61·5–73·3) 69·2 (57·8–75·0) 68·5 (62·0–74·1)
WHO performance status
0 85 (66%) 90 (69%) 175 (67%)
1 43 (33%) 40 (31%) 83 (32%)
Missing data 1 (1%) 1 (1%) 2 (1%)
Smoking status
Current 14 (11%) 13 (10%) 27 (10%)
Previous 67 (52%) 70 (53%) 137 (53%)
Never 47 (36%) 48 (37%) 95 (37%)
Missing data 1 (1%) 0 (0%) 1 (0%)
Concomitant drugs
No 27 (21%) 25 (19%) 52 (20%)
Yes 102 (79%) 105 (80%) 207 (80%)
Antihypertensive 51 (40%) 60 (46%) 111 (43%)
Analgesic 30 (23%) 21 (16%) 51 (20%)
Antidiabetes 11 (9%) 15 (11%) 26 (10%)
Anticoagulant 19 (15%) 9 (7%) 28 (11%)
Antiangina 7 (5%) 7 (5%) 14 (5%)
Other 80 (62%) 77 (59%) 157 (60%)
Missing data 0 (0%) 1 (1%) 1 (0%)
Pathological T stage
pT2 30 (23%) 44 (34%) 74 (28%)
pT3 88 (68%) 83 (63%) 171 (66%)
pT4 11 (9%) 4 (3%) 15 (6%)
Nodal stage*
N0 118 (91%) 118 (90%) 236 (91%)
N1 7 (5%) 8 (6%) 15 (6%)
N2 4 (3%) 4 (3%) 8 (3%)
N3 0 (0%) 1 (1%) 1 (0%)
GFR (mL/min)
30–49 45 (35%) 49 (37%) 94 (36%)
≥50 84 (65%) 82 (63%) 166 (64%)
Site of tumour
Renal pelvis 44 (34%) 47 (36%) 91 (35%)
Ureter 42 (33%) 47 (36%) 89 (34%)
Both 40 (31%) 37 (28%) 77 (30%)
Missing data 3 (2%) 0 (0%) 3 (1%)
Type of surgery
Open 17 (13%) 21 (16%) 38 (15%)
Laparoscopic 104 (81%) 109 (83%) 213 (82%)
Robotic 4 (3%) 1 (1%) 5 (2%)
Other† 1 (1%) 0 (0%) 1 (0%)
Missing data 3 (2%) 0 (0%) 3 (1%)
(Table continues on next page)
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carboplatin, because this number does not match the one 
below or in figure 1?] Median follow-up was 30·3 months 
(IQR 18·0–47·5).
95 (75%) of 126 participants who started chemo-
therapy received all four planned cycles (52 gemcitabine-
cisplatin and 43 gemcitabine-carboplatin [A: please 
check numbers because figure 1 shows 42 gemcitabine-
cisplatin and 53 gemcitabine-carboplatin]). 31 participants 
discontinued chemotherapy early (clinician’s decision 
[n=11], toxicity [n=10], patient’s choice [n=8], or another 
unspecified reason [n=2]). The proportion of patients 
who completed four cycles of chemotherapy did not 
differ by planned platinum agent (gemcitabine-cisplatin, 
57 of 81 [70%] [A: 42 of 71 or 76?]; gemcitabine-carboplatin, 
38 of 52 [73%] [A: 53 of 55 or 50?]; p=0·74). [A: again, 
these numbers cannot be calculated from figure 1, please 
check them] 41 (58%) of 71 [A: 42 in figure 1] patients 
who started cisplatin completed four cycles of cisplatin. 
198 (91%) of 218 cycles of gemcitabine-cisplatin and 
186 (83%) of 223 cycles of gemcitabine-carboplatin 
were delivered without a dose reduction. 16 (21%) of 
76 participants intended for cisplatin switched to carbo-
platin because of a post-randomisation drop in GFR 
(figure 1). Six participants switched before the start 
of treatment and a further ten patients changed 
chemotherapy regimen from gemcitabine-cisplatin to 
gemcitabine-carboplatin at cycle two or later; of these, 
six switches were because of a reduction in GFR, as 
per protocol, two were attributable to suspected renal 
impairment, and two were because of grade 3 toxicity 
(joint pain or tinnitus). One (2%) of 50 participants 
planned to receive carboplatin switched to cisplatin 
because of a post-randomisation increase in GFR before 
treatment began.
Fewer disease-related events contributing to the 
primary endpoint were reported in participants allocated 
chemotherapy (35 of 131 [27%]) than in participants 
allocated surveillance (60 of 129 [47%]). Chemotherapy 
conferred a 55% reduction in relative risk of disease 
recurrence or death (HR 0·45, 95% CI 0·0–0·68; log-
rank p=0·00011; figure 2A). 3-year disease-free survival 
estimates were 71% (95% CI 61–78) in patients allo-
cated chemotherapy and 46% (36–56) in those allocated 
surveillance, with an estimated absolute difference of 
25% (95% CI 11–38). Median disease-free survival 
among patients allocated surveillance was 29·8 months 
(IQR 6·3–not reached [NR]; 95% CI 13·6–incalculable), 
and was not reached among those allocated chemotherapy. 
The benefit of chemotherapy was largely unchanged 
after adjustment for known prognostic factors (HR 0·46, 
95% CI 0·30–0·71; p=0.00036; appendix p 6). Sensitivity 
analyses, including second primary muscle-invasive blad-
der cancers as recurrence events, gave similar results 
(appendix p 7). No heterogeneity of disease-free survival 
treatment effect was seen by prespecified balancing 
factors or tumour stage (figure 3).
Participants allocated chemotherapy also had a lower 
risk of metastasis (HR 0·48, 95% CI 0·31–0·74; log-rank 
p=0·00072; figure 2B). 3-year event-free rates were 71% 
(95% CI 60–79) among patients allocated chemotherapy 
Figure 2: Disease-free survival and metastasis-free survival
Shaded areas denote 95% CIs. HR=hazard ratio. [A: please provide number 
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Number of lymph nodes dissected
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4–9 6 (5%) 6 (5%) 12 (5%)
≥10 6 (5%) 3 (2%) 9 (3%)
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Table: Participants’ and tumour characteristics at trial entry
See Online for appendix
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and 53% (42–63) among those allocated surveillance, 
with an estimated absolute difference of 17% (95% CI 
4–31). Results were similar in multivariable analyses 
(appendix p 6).
Analysis of overall survival is planned once 88 deaths 
have occurred or all participants have at least 2 years 
of follow-up (whichever occurs first). 62 deaths have 
been recorded to date (24 assigned chemotherapy and 
38 assigned surveillance). 49 deaths were attributed to 
UTUC, four to bladder cancer, one to other malignant 
disease, and eight to other causes. No treatment-related 
deaths were reported.
Grade 3 or worse acute treatment-emergent adverse 
events were reported for 55 (44%) of 126 participants 
who started chemotherapy (31 of 71 [44%] who started 
gemcitabine-cisplatin and 24 of 55 [44%] who started 
gemcitabine-carboplatin) compared with five (4%) of 
129 managed by surveillance (p<0·0001). For each chemo-
therapy regimen, adverse events accorded with those 
frequently reported in routine clinical practice (appendix 
pp 8–11). Patients who received chemotherapy were more 
likely than those managed by surveillance to have grade 3 
or worse decreases in neutrophils (45 of 126 [36%]) and 
platelet count (13 of 126 [10%]), nausea (eight of 126 [6%]), 
febrile neutropenia (eight of 126 [6%]), and vomiting 
(seven of 126 [6%]). 54 serious adverse events were 
reported for 42 (32%) of 131 participants allocated che-
motherapy; 39 events were related to treatment. Analysis 
of late toxicity is planned once 2-year data are available 
for all participants.
256 (98%) of 261 study participants consented to take 
part in the optional patient-reported quality-of-life study, 
including one participant who withdrew consent to use 
data after randomisation. Questionnaire return rates 
did not differ by allocated study group at any timepoint. 
Questionnaires were returned by 243 (95%) of 255 par-
ticipants at baseline (119 [95%] of 125 allocated surveil-
lance and 124 [95%] of 130 allocated chemotherapy), 
208 (82%) at 3 months (101 [81%] and 107 [82%], respec-
tively), and 166 (70%) at 12 months (78 [70%] and 
88 [70%], respectively). Mean overall global health status 
score at baseline was 77% (SD 19) for the chemotherapy 
group and 76% (19) for the surveillance group. Overall 
global health status was lower during chemotherapy 
(before cycle 3) and immediately afterwards (at 3 months) 
in participants allocated chemotherapy versus surveil-
lance. This difference had resolved by 6 months (figure 4). 
A full quality-of-life data analysis is planned once 2-year 
data are available for all participants.
Discussion
To our knowledge, the POUT trial is the largest reported 
in this patient population. Our findings show that 
gemcitabine-platinum combination chemotherapy initi-
ated within 90 days after nephroureterectomy signifi cantly 
improves disease-free survival in patients with locally 
advanced UTUC. Chemotherapy was also associated with 
improved metastasis-free survival, with acceptable acute 
toxic effects consistent with existing data,11 and with no 
more than a transient effect on patient-reported quality of 
life.
The relative effect on survival of carboplatin and 
cisplatin remains unclear in urothelial carcinoma with-
out sufficient data from clinical trials incorporating a 
direct randomised comparison between the two agents. 
Findings of a meta-analysis of outcomes of patients with 
advanced urothelial carcinoma treated with platinum-
based chemotherapy showed superior tumour response 
rates in trials of cisplatin compared with those of 
carboplatin.12 In the POUT trial, a GFR greater than 
50 mL/min was deliberately selected as the criterion for 
cisplatin delivery. Appropriate selection of the cisplatin-
eligible population was an important consideration 
during development of the POUT trial, with input 
sought from potential investigators. Although we 
acknowledge that a GFR lower than 60 mL/min forms 
part of the Galsky definition of being cisplatin unfit, 
Figure 3: Subgroup analysis of disease-free survival
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routine practice in the UK for treatment of patients with 
non-UTUC tumours is to use a cutoff point for GFR 
greater than 50 mL/min. In view of UK oncologists’ 
experience and familiarity with use of cisplatin in 
patients without UTUC, and our wish not to exclude 
patients in the rare UTUC setting for whom cisplatin 
could be a feasible treatment, we judged that the 
criterion for switching to carboplatin at a GFR less than 
50 mL/min was appropriate.
Acknowledging low power for formal statistical testing, 
our analysis showed no apparent heterogeneity of 
treatment effect and results were consistent across 
prespecified subgroups, including planned platinum 
agent. POUT trial data, therefore, support the use of 
adjuvant platinum-based chemotherapy in all patients 
who have undergone nephroureterectomy with curative 
intent. Although cisplatin should be the preferred 
agent when possible, our results suggest that patients 
for whom cisplatin is contraindicated because of poor 
renal function could still derive benefit from the 
alternative gemcitabine-carboplatin regimen. Individuals 
with resected nodal disease and those with micro-
scopically positive margins at surgery should also be 
offered adjuvant platinum-based chemotherapy, subject 
to their fitness for systemic treatment.
The limitations of our study largely relate to pragmatic 
decisions taken during study development to enable 
successful recruitment to this trial in a rare patient 
population while preserving our ability to address the 
primary endpoint.
At the time of study development, a feasibility survey 
across all UK sites confirmed that formal nodal dissection 
was not part of standard care, nor were data to support 
this procedure strong. Therefore, nodal dissection was 
not mandated in the protocol because it was deemed 
inappropriate. Ongoing debate around the survival 
benefits of extended abdominal lymph node dissection 
(ELND) in UTUC13 meant that this procedure was only 
needed for patients with observable lymphadenopathy on 
baseline imaging. Since most participants had limited 
[A: what do you mean by limited here?] lymph node 
dissection, occult metastases might have been overlooked 
in some patients categorised as N0, because a proportion 
were likely to have been microscopically node-positive. A 
clear benefit from adjuvant chemotherapy was seen in 
the N0 group of patients; therefore, whether standard 
use of nodal dissection would offer additional benefit is 
uncertain. The role of ELND in N0 disease remains a 
subject for future studies.
We acknowledge that disease-free survival is not 
regarded as a fully validated surrogate of overall survival 
after nephroureterectomy for UTUC.13 However, in a rare 
disease such as UTUC, a suitably powered trial with 
overall survival as the primary endpoint was not judged 
feasible. A placebo control group was judged inappro-
priate; use of identical follow-up procedures in both 
study groups aimed to minimise the risk of assessment 
bias. Although mature survival data (as a secondary 
endpoint) are not yet available, the large improvement in 
disease-free survival we noted for the primary endpoint, 
together with improved metastasis-free survival recorded 
as a secondary endpoint, strongly suggest that patients 
have better outcomes with chemotherapy than without. 
In view of the rarity of UTUC and the urgent need 
to improve outcomes, we believe that evidence is 
now sufficient to advocate use of gemcitabine-platinum 
combination chemotherapy as a standard of care.
Whether perioperative systemic therapy would be most 
effective for UTUC in the neoadjuvant or adjuvant setting 
remains contentious. Meaningful pathological complete 
response rates14 and, in retrospective case series, survival 
benefits15 suggest similar potential advantages with 
neoadjuvant therapy in UTUC to those seen in bladder 
cancer. Furthermore, potentially nephrotoxic cisplatin-
based chemotherapy might be safer and more feasible for 
UTUC if given before nephroureterectomy, when patients 
retain maximum renal function. Some patients were 
probably excluded from the POUT trial (and might be 
similarly excluded from adjuvant chemotherapy in real-
life practice) because of insufficient recovery after surgery. 
These patients might be better served with neoadjuvant 
chemotherapy, albeit with the risk that the toxic effects 
of chemotherapy could prevent some individuals from 
proceeding with curative surgery. We had considered a 
trial of neoadjuvant chemotherapy when developing the 
POUT trial concept; however we had concerns about the 
reliability of preoperative staging and histology in muscle-
invasive UTUC.6 Before starting the POUT trial, we did 
a feasibility survey across all potential UK investigators, 
which strongly supported an adjuvant rather than a 
neoadjuvant study for the reasons we have outlined. 
Two patient focus groups undertaken during study 
development explored the different approaches, and their 
feedback favoured an adjuvant trial. Investigation of the 
relative feasibility of adjuvant and neoadjuvant cytotoxic 
chemotherapy in UTUC is underway (NCT02969083). 
Although the POUT trial has shown superiority of adju-
vant chemotherapy over surgery alone, it is not clear that 
patients previously planned for neoadjuvant chemotherapy 
should now defer treatment until surgery is complete. 
However, until further robust evidence becomes available, 
we propose that adjuvant treatment should be considered 
the preferred setting for future trials of perioperative 
chemotherapy in UTUC.
Previous studies adding a third agent to gemcitabine-
platinum combinations have met with little success in 
advanced disease,16–18 partly because of the high burden of 
toxicity. However, data suggest potential benefits from 
two new classes of agents, fibroblast growth factor 
receptor (FGFR) inhibitors and immune checkpoint 
therapeutics. Increased understanding of the biology of 
UTUC suggests that distinct molecular differences exist 
between UTUC and bladder urothelial carcinomas.19 
Higher proportions of FGFR alterations and luminal-like 
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urothelial cancer signatures have been noted in UTUC20 
than in bladder cancer.21 Because the former molecular 
type is associated with high response rates to FGFR 
inhibitors and the latter with low response rates to 
chemotherapy in advanced urothelial cancers, [A: please 
say exactly what you mean by former and latter here] 
investigation of orally bioavailable FGFR inhibitors (eg, 
erdafitinib alone or in combination with gemcitabine-
platinum regimens in molecularly selected patient 
cohorts) might have particular value.22–25 Efficacy of check-
point inhibitors (eg, pembrolizumab and atezolizumab in 
advanced urothelial carcinoma)26–28 has prompted trials of 
immunotherapy in the perioperative setting as mono-
therapy and in combination with cytotoxic chemotherapy 
for urothelial or bladder carcinomas [A: please check, 
you used an unfamiliar abbreviation] (eg, NCT02365766 
and NCT03661320). Although the adjuvant trials have 
included preplanned cohorts of patients with UTUC, no 
phase 3 trials are underway to address the role of immu-
notherapy in the adjuvant treatment of UTUC alone. Both 
FGFR inhibitors and immune checkpoint inhibitors 
might, therefore, be suitable additions to chemotherapy in 
future phase 3 trials that specifically address optimisation 
of perioperative treatment in UTUC.
We conclude that adjuvant platinum-based chemo-
therapy should be adopted as a new standard of care for 
patients with locally advanced UTUC for whom systemic 
chemotherapy is not contraindicated. This regimen 
should be routinely considered for all patients in this 
population, and future studies should focus on combi-
nations with novel agents in the adjuvant setting, which 
might further improve the prognosis for locally advanced 
UTUC.
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